- Home
- RPRX vs EVR Comparison
RPRX vs EVR Comparison
Compare RPRX & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- EVR
- Stock Information
- Founded
- RPRX 1996
- EVR 1995
- Country
- RPRX United States
- EVR United States
- Employees
- RPRX N/A
- EVR N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- EVR Investment Managers
- Sector
- RPRX Health Care
- EVR Finance
- Exchange
- RPRX Nasdaq
- EVR Nasdaq
- Market Cap
- RPRX 13.9B
- EVR 11.6B
- IPO Year
- RPRX 2020
- EVR 2006
- Fundamental
- Price
- RPRX $37.85
- EVR $300.11
- Analyst Decision
- RPRX Strong Buy
- EVR Buy
- Analyst Count
- RPRX 4
- EVR 8
- Target Price
- RPRX $46.75
- EVR $294.38
- AVG Volume (30 Days)
- RPRX 2.5M
- EVR 609.7K
- Earning Date
- RPRX 08-06-2025
- EVR 07-30-2025
- Dividend Yield
- RPRX 2.38%
- EVR 1.13%
- EPS Growth
- RPRX 43.84
- EVR 52.07
- EPS
- RPRX 2.16
- EVR 11.01
- Revenue
- RPRX $2,304,578,000.00
- EVR $3,238,871,000.00
- Revenue This Year
- RPRX $28.60
- EVR $10.19
- Revenue Next Year
- RPRX $8.07
- EVR $24.33
- P/E Ratio
- RPRX $17.14
- EVR $27.04
- Revenue Growth
- RPRX 2.99
- EVR 23.41
- 52 Week Low
- RPRX $24.05
- EVR $148.63
- 52 Week High
- RPRX $38.00
- EVR $324.06
- Technical
- Relative Strength Index (RSI)
- RPRX 57.95
- EVR 57.90
- Support Level
- RPRX $36.27
- EVR $296.03
- Resistance Level
- RPRX $38.00
- EVR $304.47
- Average True Range (ATR)
- RPRX 0.68
- EVR 7.16
- MACD
- RPRX -0.02
- EVR -2.16
- Stochastic Oscillator
- RPRX 64.97
- EVR 41.16
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About EVR Evercore Inc.
Evercore Inc is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,380 employees at the end of 2024, and about 75% of its revenue is derived from the United States.